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Protein phosphorylation is a key post-translational modification (PTM) in many biological processes and 
is associated to human diseases such as cancer and metabolic disorders. The accurate identification, 
annotation and functional analysis of phosphosites is therefore crucial to understand their various 
roles. Phosphosites (P-sites) are mainly analysed through phosphoproteomics, which has led to 
increasing amounts of publicly available phosphoproteomics data. Several resources have been built 
around the resulting phosphosite information, but these are usually restricted to protein sequence 
and basic site metadata. What is often missing from these resources, however, is context, including 
protein structure mapping, experimental provenance information, and biophysical predictions. We 
therefore developed Scop3P: a comprehensive database of human phosphosites within their full 
context. Scop3P integrates sequences (UniProtKB/Swiss-Prot), structures (PDB), and uniformly 
reprocessed phosphoproteomics data (PRIDE) to annotate all known human phosphosites. 
Furthermore, these sites are put into biophysical context by annotating each phosphoprotein with per-
residue structural propensity, solvent accessibility, disordered probability, and early folding information. 
Scop3P, available at https://iomics.ugent.be/scop3p, presents a unique resource for visualization and 
analysis of phosphosites, and for understanding of phosphosite structure-function relationships.  
 




Post-translational modifications (PTMs) are typically the result of the addition of a small molecule 




than 200 PTMs currently identified. Protein phosphorylation, a reversible PTM, is one of the best 
studied PTMs and is involved in many regulatory processes 3,4. Protein phosphorylation is regulated 
by three core machineries, namely kinases, phosphatases, and proteins which recognize the 
phosphorylation signals/P-sites 5. Kinases, one of the largest protein families, can be considered as 
the writers of protein phosphorylation: they add a highly negatively charged phosphate group to the 
side chain of serines, threonines, and tyrosines and less frequently to cysteines and histidines 6. 
These phosphorylation signals can be recognized by phospho binding proteins – the readers – which 
interact with phosphorylation signals and proteins7. Phosphatases, the erasers of the phosphate 
group, function opposite to kinases: they remove the phosphate group from phosphorylated residues 
7,8.  
Several studies have attempted to differentiate between functional and non-functional P-sites based 
on their evolutionary conservation9,10, kinase specificity 11,12, PTM cross-talk or based on their 
interactions 13. However, P-site conservation may not be particularly useful to determine functional 
importance of a P-site as only a small fraction (~35%) of functional P-sites were reported to be 
conserved 14,15, while some functional P-sites have been identified in poorly conserved regions 11,16. 
Most of the conserved but non-functional P-sites have been accumulated due to the off-target effect 
of kinases 11 in disordered regions of proteins as these are more accessible to kinases than ordered 
regions are 17.  
The dominant means of discovering novel P-sites is mass spectrometry (MS) based 
phosphoproteomics, which has been the primary driver for the expansion of the known P-sites. With 
the increasing public availability of data from such proteomics experiments 18, several databases 
related to one or more PTMs in one or more model organisms have been established. For instance, 
O-GLYCBASE 19 is an information repository of the glycosylation status of proteins, while the 
Human Protein Reference Database (HPRD) 20 contains information on experimentally annotated 
PTMs of human proteins, and dbPTM 21 contains experimentally verified as well as 




Phospho.ELM 23, Phospho3D 24, PhophositePlus 25, and database of Phospho-sites in Animals and 
Fungi (dbPAF) 26 are all databases that focus on P-sites specifically and contain information about 
the sequence and/or structural features of experimentally determined P-sites. Many of these sites are 
also reported in UniProtKB/Swiss-Prot 27, which contains both functional and structural annotations 
of proteins, but lacks direct access to important structural properties related to P-sites. Most of the 
abovementioned repositories collect and integrate a large number of P-sites from different sources 
or MS experiments, but provide very little or no information on the functional role(s) of these P-
sites. Moreover, the phospho-peptides measured in different phosphoproteome experiments are 
typically identified with different search engines and different false discovery rate (FDR) 
thresholds, which may artificially increase the heterogeneity of P-sites when these are integrated 
into a database which has no information on the significance of the reported P-sites 28. This issue 
can be mitigated by analyzing the entire data set as one, thus allowing the control of the global FDR 
threshold 29. 
Because of the difficult and time-consuming process of experimental identification of P-sites, 
several computational P-site prediction algorithms have been developed 30–33. These predictors are 
typically trained on data obtained from the above described public resources or on the observation 
of kinase specificity and sequence features to predict if a particular site can be phosphorylated. 
However, these predictors provide very little to no information on whether the site is functional or 
not. They also often neglect the importance of conformational specificity of kinases34 and of 
structural dynamics upon phosphorylation/de-phosphorylation 35, which can lead to incorrect or 
non-confident P-site predictions. 
Because the function of a protein and the corresponding signaling cascades are highly correlated 
with protein structure, and because phosphorylation status can result in protein structural re-
arrangements 36,37, it is important to know where a phosphorylation is located on the protein 




protein structures can provide such insight by presenting researchers with an overview of the spread 
of P-sites over the three-dimensional structure of a protein. 
Beyond the structural context itself, there is also the biophysical context of a residue. Indeed, 
adding or removing a negatively charged phosphate group alters a residue’s electrostatic potential 
38,39. This alteration may serve as a recognition site for phospho binding proteins but can also trigger 
conformational transitions in the phosphoprotein. Phosphorylation can moreover modulate the 
binding specificity of phosphoprotein binding proteins by offering a wide range of recognition 
patterns based on conserved amino acid residues close to the P-sites 40,41. Moreover, studies have 
shown an association between phosphorylation/de-phosphorylation events and order-disorder 
transitions that are in turn coupled with binding regulation 38,42–44. 
It is thus clear that a thorough analysis of the biological relevance and possible role of a given P-site 
needs to take place against the full context of that P-site, which consists of the P-site localization in 
the protein, its structural characteristics, its experimental provenance, and its biophysical properties. 
 
Here we therefore present Scop3P, a database of human P-sites in their full context. To do so, 
Scop3P provides annotation for all known human P-sites based on protein sequence, 3D structure, 
and biophysical predictions. Moreover, Scop3P is unique in that it also provides a reliability 
measurement for each P-site based on the frequency with which that phosphorylation has been seen 
across different phosphoproteomics experiments. Importantly, these phosphoproteomics results 
have been obtained by a uniform, large scale re-analysis of phosphoproteomics data from the 
PRIDE database 45, and have been filtered by a global FDR to high reliability. In addition, Scop3P 
contains secondary structural propensity (helix, sheet, coils), solvent accessibility, and biophysical 
properties such as the probability of being a disordered region, backbone dynamics, and functional 
information related to phosphoproteins. Importantly, every phosphoprotein is also annotated with 




dynamics of the protein. By providing information on early folding regions/residues, Scop3P adds 
further unique information on whether or not a phospho acceptor residue is crucial in forming local 
structural elements that influence the final fold of a protein.    
Methods 
 
To create Scop3P we collected and integrated all available P-sites from different data sources (Fig 
2A-C, Table 1). First, we retrieved all available human P-sites from UniProtKB/Swiss-Prot 
27(release-2018_02) by parsing UniProtKB/Swiss-Prot MOD_RES records. For every P-Site the 
evidence annotation (experimentally determined, or by similarity) and the associated reference 
information were also obtained.  
 
Re-processing of human phosphoproteomics data from PRIDE 
 
We retrieved a list of all Human projects which are annotated to contain phosphorylations from 
PRIDE 45. Only those projects which are unlabeled and submitted as complete projects containing 
high resolution spectra files were considered (see supporting information Table S1). In total 2016 
RAW files containing 60.2 million (60,248,401) spectra from 36 different projects were retained for 
processing. These projects were typically originally processed with different search engines and 
different search settings. In order to obtain uniform data, we collected all ‘.RAW’ files from PRIDE 
and converted these to Mascot Generic Format (MGF) peak files using ThermoRawFileParser47 
(Hulstaert et al, 2019). The resulting peak files were then searched against the human complement 
of UniProtKB/Swiss-Prot (release-2018_02, containing 20259 protein sequences) with the 
target/decoy approach using ionbot (https://ionbot.cloud/; ionbot is based on MS2PIP 48–50 and 
ReScore 51,52). Results were filtered at 1% FDR. The ionbot engine searches for all modifications 
listed in Unimod 53 on top of a set of user-defined fixed and variable modifications. The search 




oxidation of methionine, phosphorylation of serine (S), phosphorylation of threonine (T), and 
phosphorylation of tyrosine (Y) were set as variable modifications. Up to two missed cleavages per 
peptide were allowed. Only identified peptides with q-values <0.01 were considered for further 
analysis. In total, we identified 19.2 million (19,267,603) PSMs (peptide spectrum matches) with 
1% FDR resulting in 139,048 P-sites. The localization probability for the P-sites was assigned using 
PhosphoRS 54 which was adapted to accept ionbot output files as input. If there are multiple peptide 
spectrum matches (PSMs) or multiple peptides for a given P-site, then the P-site was only included 
if a site probability of at least 0.5 was found in at least one of these identifications.  This resulted in 
the removal of 32.3% (44,937 out of 139,048) of identified P-sites after applying this filter. As a 
result, a total of 94,111 P-sites with site probablity of ≥ 0.5 was only considered for further analysis. 
The total search time was 12 days on a single Linux server with 24 cores and 30 GB of RAM 
memory. 
 
Structural properties of the phosphoproteins 
 
For every human phosphoprotein for which at least one structure was available, the modeled 
segment of the UniProtKB/Swiss-Prot sequence in the protein structure was scanned to check if any 
P-sites were within range of that segment. If the modeled segment contained at least one such P-
site, the corresponding PDB 55,56 structure was used to map and visualize all matching P-sites. P-
sites that fell in missing segments of structures were not considered for structural mapping. The 
oligomeric state of the protein structure, solvent accessibility of the P-sites, and exposure level 
(buried, exposed, or in an interface region) were obtained from the Protein Interfaces, Surfaces and 
Assemblies (PISA) server (also known as PDBePISA) 57. The interface details were obtained by 
taken into consideration the most probable quaternary structure as assigned by PISA. PISA predicts 
quaternary structures based on the interactions occurring in macromolecular crystals (pair of chain 




structure were retrieved from DSSP 58. The eight-class classification of DSSP was grouped into 
three states (helix (H): ‘alpha helix, 3/10 helix, pi helix’, strand (E): ‘extended strand, residue in 
isolated beta-bridge’, and loop (C): ‘turn, bend and the rest’).  Every structure is also annotated 
with its determination method, resolution, and stoichiometry details. 
 
For all phosphoproteins, regardless of existing structure match, the three states of the secondary 
structural propensity (helix (H), coil (C), sheet (E)) were predicted using Fast Estimator of 
Secondary structures (FESS), which is a component of the FELLS method 59. Protein biophysical 
characteristics such as backbone dynamics, disordered propensity, and early folding properties were 
predicted using DynaMine 60, DisoMine (http://bio2byte.com/disomine), and EfoldMine 46, 
respectively. DynaMine predicts the residue-level backbone flexibility in the form of S2 values 
between 0 (highly dynamic) and 1 (stable conformation), which represents how restricted the 
movement of the atomic bond vector is with respect to the molecular reference frame. For 
DisoMine, the probability cutoff of 0.5 distinguishes the (predicted) ordered and disordered state of 
the protein. EfoldMine predicts the early folding (EF) propensity of amino acids based on local 
interactions, and as such provides insight into which amino acids are likely involved in early stages 
of protein folding and thus shape the folding landscape of that protein. The EF propensities and 
binary classification based on a 0.163 probability cutoff were used to distinguish between early 
folding and non-early folding residues. 
 
Conservation and variation of amino acids in phospho acceptor residues 
 
Known amino acid variations for P-sites (phospho variants) or for sites in their close proximity may 
result in functional variants, e.g., through a change in kinase specificity, loss and gain of P-sites, 
and diseases 61. In order to map such variants on both sequence and structure, we retrieved all 




UniprotKB/Swiss-Prot (Fig 2A, Table 1) that are classified as disease/polymorphisms/unclassified 
based on their role in disease. Humsavar data contains all manually curated single amino acid 
polymorphisms as retrieved from literature that are associated with diseases and phenotypes. In total 
it contains 78,882 variants of which 40% are associated with diseases. We also obtained the 
evolutionary conservation from AMINODE 62 for all P-sites mapped to a structure (Fig 2A, Table 
1). These conservation values ranges from 0 (variable) to 1 (conserved).  
 
Database construction, integration and content 
 
The web interface was developed using the Spring Boot framework. JQuery, Bootstrap and 
Tymeleaf were used as front-end technologies. Protein structures are visualized with the aid of NGL 
Viewer 63, and other protein visualizations such as the circular plot and ball and stick representation 
of P-sites on primary (one dimensional) amino acid sequences are developed through the D3 
javascript library. Scop3P data is stored in a relational database running on MySQL 5.7. 
 
Scop3P contains both sequence (Fig 2A,C) and structure (Fig 2B) information, for both 
phosphoproteins and for individual P-sites (Fig 1A-E). All obtained parameters were mapped to the 
amino acid sequences of the human proteins retrieved from UniProtKB/Swiss-Prot. Sequence to 
structural position mapping was done with the aid of SIFTS 64. P-sites which fell in the missing 
segments of available structures were not considered for structure mapping. Every instance with 
structure was annotated with secondary structural propensity and evolutionary conservation details 
as described earlier. Additional residue level biophysical properties such as DynaMine, DisoMine 
and EfoldMine predictions were annotated to UniProtKB/Swiss-Prot protein sequences. Moreover, 
to show the reliability of the P-sites, every P-site is annotated with the frequency of phosphorylation 
as found in the different phosphoproteomics experiments. As a second level of annotation, every P-




different PRIDE projects, and every such peptide is then annotated with its ProteomeXchange ID 65, 
and its frequency across the different PRIDE projects. 
 
 
In Scop3P, we aim to map all P-sites of a particular protein to all available three-dimensional 
structures. Thus, if a protein has more than one structure, all structures that contain at least one P-
site are retained for mapping and visualization. For each P-site with 3D structure, the assembly and 
interface details such as the macromolecule chain where the P-site is present (main chain), 
accessible surface area (ASA), buried surface area (BSA), and information about crystal contacts 




PISA assigns a value from 0 to 1 for every complex (CSS) in the biological assembly. This value is 
calculated as a fractional contribution of the particular interface to the crystal assembly. Hence, in 
Scop3P, if a particular P-site is present in a multimeric protein (with chain XYZ) at chain X, only 
the interfaces with higher CSS value for the chain X are considered. For example: if the CSS value 
for interface XY is higher than XZ then this means that this complex – composed of chain X and 
chain Y – is the most probable biological assembly as predicted by PISA. Sometimes the interacting 
molecule will be a ligand which means that the ligand is fixed with the polymer during PISA 








After populating Scop3P with all known phosphosites as obtained from UniProtKB/Swiss-Prot and 
the reprocessing of complete human phosphoproteomics experiments in PRIDE, the Scop3P 
database contains 14,261 phosphoproteins, covering 70% of the 20,259 human proteins in 
UniProtKB/Swiss-Prot. Together, these proteins contain a combined 108,130 P-sites (Table 1) of 
which 82,116 are unique P-sites (14,019 are unique to Swiss-Prot, 68,097 are unique to PRIDE) and 
26,014 sites are shared. A total of 40,033 P-sites (experimental: 30,015, by similarity 10,018) are 
obtained from UniProtKB/Swiss-Prot annotations, and 94,111 by re-processing  experimental data 
in PRIDE, of which 68,254 are singly phosphorylated (Table 1). The distribution of all P-sites in 
Scop3P shows that 69.41% of P-sites are phosphoserine, 22.29% are phosphothreonine, 8.29% are 
phosphotyrosine, and 0.002% are phosphohistidine (Table 1).  
 
The structural data in Scop3P contains 10,044 unique P-sites corresponding to 3,074 
phosphoproteins, which are in turn represented by 21,937 different structures (Table 1). The 
structures in the database are determined from different methods, including X-ray diffraction 
(96.55%), NMR (2.50%), EM (<1%), neutron diffraction (<1%), and other combinatorial methods 
(<1%). Scop3P also contains 78,882 human amino acid variants with disease information obtained 
from UniProtKB/Swiss-Prot. 80.7% (68,478) of these variants are mapped onto 10,416 
phosphoproteins. 877 of these variants fall on P-sites, and 245 of these are deleterious variants 
associated with one or more diseases (Table 1).  
 
 
Web Interface and usage of Scop3P 
 
The information in Scop3P can be accessed through the ‘search’ or ‘browse’ options (Fig 1A). The 
user can search for a protein by UniProt accession number, entry name, protein name, and 




(ID). The results page displays two levels of information: the sequence level, and the structural 
level (Fig 1A). A quick preview will be displayed in the top panel where all P-sites are mapped in 
ball and stick notation on the amino acid sequence. The coloring of the ball reflects the frequency of 
that P-site across the different phosphoproteomics projects from PRIDE.  P-sites are colored blue to 
differentiate the ones that are mapped onto the structure displayed (Fig 1A). A tooltip (triggered 
when hovering the mouse over the ball) will give additional information such as modification name, 
number of unique peptides that contain that modification, number of different PRIDE projects in 
which this P-site is seen, mutations (if any) and the mapped position on the PDB structure. A 




Data is also rendered as tables and interactive graphs. The phospho-sites table at the bottom of the 
sequence annotation gives an overview of the P-sites (Fig 1A), their source (obtained from 
UniProtKB/Swiss-Prot, from PRIDE, or from both, and, if found in UniprotKB/Swiss-Prot, the 
evidence information for the P-site (Experimental, By Similarity, or Combined for both). P-sites that 
are coming from peptides with just one phosphorylation (singly phosphorylated) are labelled as 
‘yes’. The interactive circular graph contains the residue level predicted secondary structural 
propensity, backbone dynamics, disorder, and early folding values of the protein in context (Fig 
1B). Hovering over a residue in the graph will display the values associated with that residue. As a 
point of reference, the first amino acid of the protein will be colored dark in all rings of the circular 
plot. 
 
The phospho-peptide table (Fig 1C) provides information on all PRIDE-derived peptides that 
contain one or more P-sites for a particular protein. Information such as the ProjectID, peptide 




position in the protein and peptide sequence are displayed. Hovering over the projectID will display 
project metadata such as the title, species, submission type, tissues, and publication date. By 
clicking on the drop-down icon, project information such as project id and frequency of that peptide 
in the corresponding project can be accessed. 
 
In the mutation table, known amino acid variants and their known associated diseases (if any) are 
given (Fig 1D). These variant details can also be viewed when hovering over the P-site’s ball and 
stick representation in the top panel. 
 
Finally, in the structure table (Fig 1E), all available structures for the selected protein that contain at 
least one P-site will be displayed. The idea of visualizing a particular P-site mapped onto multiple 
protein structures can give insights into the structural context in which the P-site is located in 
different structural conformations of that protein. In the overview, information such as PDB ID, 
main chain, interacting chain/molecule, secondary structural propensity, conservation scale, 
resolution and stoichiometry of the structure, and the position of the P-sites in the PDB structure 
will be displayed. By clicking on the dropdown icon, secondary structural information such as 
accessible surface area (ASA), buried surface area (BSA) is given. Upon clicking the PDB ID, a 
dedicated page for structure will be displayed where the user can color the P-sites based on solvent 
accessibility, frequency of the site across the different PRIDE projects, and neutral/deleterious 
polymorphisms (Fig 1E). A complete map of all P-sites mapped on to that particular structure can 




Scop3P is a user-friendly data resource that allows the analysis of experimentally determined 




bases, and shows how re-analysis of large scale public proteomics data sets can add an additional 
level of significance and confidence to the P-sites based on P-site frequency. Moreover, Scop3P 
also displays all structural and biophysical information that is available for a particular P-site. This 
provides additional knowledge about a P-site’s spatial location, structural propensity, and 
accessibility in the different available conformations of a protein structure. The value of this latter 
analysis option is highlighted by the fact that 6,666 of the 10,044 P-sites with an available structure 
have more than one such structure available in Scop3P. Moreover, early folding, disordered 
propensity, and backbone dynamics data will all provide valuable added information for researchers 
seeking to understand whether any phospho acceptor residues or related residues in close proximity 
are crucial for protein folding and stability. Interestingly, by re-processing phosphoproteomics data 
with the aid of the ionbot search engine (https://ionbot.cloud) we could identify and annotate 3894 
P-sites that are currently annotated as ‘by similarity’ in UniProtKB/Swiss-Prot, thus providing solid 
experimental evidence for these instances. Moreover, by re-processing we identified and annotated 
6,305 proteins that contain at least one P-site which is not annotated as P-site in UniProtKB/Swiss-
Prot. Over time, new phosphoprojects in PRIDE will be reprocessed and added to Scop3P, which 
might add further confirmed or even wholly novel P-sites to the system. The intention is that 
Scop3P will over time be extended to include other PTMs than can affect residues that can be 
phosphorylated (e.g., nitrosylation, sulfation, and glycosylation), which might help understand their 
potential competition for the same residue. Scop3P will be updated and maintained regularly, and 
will include new data from UniProtKB/Swiss-Prot and PDB, newly reprocessed PRIDE data, and 
updated data from the various biophysical property predictors. 
 
Because of its broad and unique data contents, Scop3P provides a unique and powerful resource to 
understand the impact of P-sites on human protein structure and function, and can serve as a 







Scop3P is available as a web-interface and can be accessed at https://iomics.ugent.be/scop3p. 
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Table 1. Data sources/tools and derived data integrated into Scop3P 
 
Data obtained Database Data statistics 





Human protein variants 
 
 
Variants on P-sites  





78,882 single amino acid variants mapped 
onto 12,893 proteins 
 
877 
Experimental P-sites from re-
analysis  
 
Singly phosphorylated sites  


































Solvent accessibility PDBePISA  10,044 P-sites with structural information 
Secondary structural propensity 
(experimental) 
DSSP 10,044 P-sites with structures 
Residue conservation scores AMINODE  10,044 P-sites with structures  
Backbone dynamics & 
secondary structural propensity, 
disorderd propensity,  
early folding predictions 
 
DynaMine, DisOmine,  
EfoldMine  










































Figure 1. Scop3P web-interface reveals different context information at different levels for all 
phosphosites in a phosphoprotein.  
 
For a given phosphoprotein, Scop3P provides a variety of information in tables and interactive 
graphs.  
 
A) Quick overview of all P-sites mapped onto the protein sequence as ball and stick. The color fill in 
the ball represents the number of different peptides identified for that particular site across PRIDE 
projects. This information is also presented as a table below. A tooltip over the ball will display 
additional information, while a quick preview panel on the right shows where that P-site is located 
on the protein structure. P-sites mapped onto the displayed structure (3GEF) are colored blue. B) All 
predicted biophysical properties and secondary structures are presented in an interactive circular plot 
with different concentric rings. The graph can be zoomed to focus on a region of interest (inner 
panel). C) Identified phospho peptides, source projects, and frequency information are presented in 




Mutation table provides information on amino acid variants, type of polymorphism, and associated 
diseases (if any). E) Information related to structures, their secondary structure information, and P-
sites mapped onto the particular structure are displayed in an overview table. Clicking the view 
structure icon will launch the structure viewer and shows P-sites mapped onto that particular 
























Figure 2. Scop3P data collection and integration flow.  
A) Sequence level information like experimental phosphosites (P-sites) obtained from re-
processed public proteomics data from PRIDE (36 projects), single amino acid variations and the 
associated disease and polymorphism details  from Humsavar dataset and the amino acid 
conservation of P-sites from AMINODE were integrated onto the amino acid sequence of 
proteins. B, C) All available P-sites from Swiss-Prot along with other structural information 
(secondary structures from DSSP, solvent accessibility from PISA) for all P-sites (Swiss-
Prot+PRIDE) and predicted residue level biophysical properties of phosphoproteins (disorder and folding 
Propensities and backbone dynamics) were integrated on amino acid sequences. Sequence to structure 










































































Simulated phosphopeptide spectral 
library for confident site 
localization 
2015-03-17 PARTIAL HeLa cell 
2 PXD000612 
Ultra-deep human 
phosphoproteome reveals different 
regulatory nature of Tyr and 
Ser/Thr-based signaling 
2014-08-06 PARTIAL cell culture 
3 PXD000836 
HOPE-fixation of lung tissue 
allows retrospective proteome and 
phosphoproteome studies 
2014-05-22 PARTIAL lung 
4 PXD001060 Fe-IMAC column based phospho 
enrichment 2015-08-19 PARTIAL Epithelial cell 
5 PXD001170 AML_profiling 2017-02-16 PARTIAL blood 
6 PXD001333 
Anion-Exchange Chromatography 
of Tryptic and Phosphopeptides: 
WAX vs. SAX and AEX vs. 
ERLIC 
2015-04-23 PARTIAL HeLa cell 
7 PXD001374 
Label-free quantitative 
phosphoproteomics with novel 
pairwise abundance normalization 
reveals synergistic RAS and CIP2A 
signaling 
2015-08-24 PARTIAL HeLa cell 
8 PXD001546 
Reproducibility of label-free single-
shot phosphoproteomics applied to 
CRC cell lines 
2015-04-15 PARTIAL cell culture 
9 PXD001550 Human CRC cell line baseline 
phosphoproteomics 2015-04-15 PARTIAL cell culture 
10 PXD000089 
Proteomic and phosphoproteomic 
data of colorectal cancer tissues and 
cells for Chromosome-Centric 
Human Proteome Project 
2013-01-11 PARTIAL colorectal cancer tissues 
11 PXD001565 
Evaluation of phospho-tyrosine 
antibodies for label-free 
phosphoproteomics 
2015-12-09 PARTIAL colon,brain 
12 PXD002255 Enrichment strategy for searching 
missing protein 2015-07-14 COMPLETE cell culture,blood serum 
13 PXD002286 
Phospo-proteomic profiling of 
Castration Resistant Prostate 
Cancer 





Proteomic and phosphoproteomic 
analysis of cisplatin resistance in 
patient derived serous ovarian 
cancer 
2017-05-02 PARTIAL cell suspension culture 
15 PXD002646 
A systematic evaluation of nanocast 
metal oxide microspheres for 
phosphoproteomics applications 
2017-05-17 PARTIAL HEK-293 
16 PXD002990 
Complementary Phosphoproteomic 
Approaches Link IL-23R 
Downstream Signaling with 
Metabolic Adaptation in 
Lymphocytes 
2016-04-21 COMPLETE lymph node 
17 PXD003198 
Characterisation of pancreatic 
ductal adenocarcinoma subtypes by 
global phosphotyrosine profiling 
2016-06-09 PARTIAL pancreatic cell line 
18 PXD003531 Proteomics of Primary cells derived 
from Ovarian Cancer 2017-04-03 PARTIAL primary cell 
19 PXD004252 
Modulating the selectivity of 
affinity absorbents to multi-
phosphopeptides by a novel 
competitive substitution strategy 
2016-08-03 PARTIAL cell culture 
20 PXD004415 
Quantitative phosphoproteome 
analysis of cisplatin-induced 
apoptosis in Jurkat T cells 
2017-05-11 COMPLETE T lymphocyte 
21 PXD004447 
Mirroring the charged termini; 
ETD/HCD fragmentation 
characteristics of LysargiNase and 
tryptic peptides and their benefits 
for peptide sequencing in 
proteomics 
2016-12-02 PARTIAL cell culture 
22 PXD004452 HeLa proteome of 12,250 protein-
coding genes 2017-06-12 PARTIAL liver,colon 
23 PXD004940 
Performance of the Orbitrap Fusion 
Lumos Tribrid in single-shot 
analyses of human samples 
2017-03-09 PARTIAL HeLa cell 
24 PXD005366 
Robust, sensitive and automated 
phosphopeptide enrichment 
optimized for low sample amounts 
applied to primary hippocampal 
neurons 
2016-12-14 PARTIAL Cell culture 
25 PXD000674 PeptideShaker 2014-01-27 COMPLETE HeLa cell 
26 PXD006114 
Phosphoproteomics of in vivo 
resistance to EGFR-targeted 
therapy in lung cancer cells 
2017-08-28 COMPLETE Epithelial cell, cell culture 
27 PXD003215 
A Novel Method for Isolating 
Whole Protein from Human Cranial 
Bone 
2016-10-05 COMPLETE Osteocyte,Cranium,Osteoblast 
28 PXD003657 
Antibody-independent 
identification of bovine milk-
derived peptides in breast-milk 
2016-07-19 COMPLETE Milk samples 
29 PXD003660 Early Signaling Dynamics of EGFR 2016-06-24 COMPLETE Epithelial cell, cell culture 
30 PXD003709 Preferential phosphorylation on old 
histones during early mitosis in 






Proteomic analysis identifies novel 
pathways linking epithelial-to-
mesenchymal transition with 
resistance to HER2-targeted therapy 
2016-02-22 COMPLETE cell culture 
32 PXD002436 
Monitoring cellular 
phosphorylation signaling pathways 
into chromatin and down to the 
gene level 
2015-11-09 COMPLETE HeLa cell 
33 PXD000964 MS approach assessment and Mad1 
phosphopeptide analysis 2014-10-31 COMPLETE cell culture 
34 PXD000680 
Stable isotope labeling of 
phosphoproteins for large-scale 
phosphorylation rate determination 
2014-04-15 COMPLETE HeLa cell,HEK-293 cell 
35 PXD000218 
System-level analysis of cancer and 
stomal cell specific proteomes 
reveals extensive reprogramming of 
phosphorylation networks by tumor 
microenvironment 
2014-04-01 COMPLETE Epithelial cell, colon 
36 PXD006482 
Identification of Missing Proteins in 
the Phosphoproteome of Kidney 
Cancer 
2017-09-01 COMPLETE kidney 
 
